RO7790121 as Treatment for Moderately to Severely Active Ulcerative Colitis: Efficacy and Health-Related Quality of Life Improvements: Results from the Phase IIb TUSCANY-2 Trial

Authors
Category Primary study
ConferenceAdvances in Inflammatory Bowel Diseases Annual Meeting, AIBD 2024
Year 2024
This article has no abstract
Epistemonikos ID: 20a85c69003b63c07c27708fcc2ffe2945760820
First added on: Mar 15, 2025